Study #2006-0328
Phase II Study of Hyper-CVAD plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Venetoclax, Vincristine Sulfate
Description
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Study phase:
Phase II
Physician name:
Farhad Ravandi-Kashani
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.